Navigation Links
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
Date:8/3/2009

reated patients (P < 0.0001). During the double-blind phase of the study, fewer patients treated with INVEGA(R) SUSTENNA(TM) experienced a relapse (10% [n=15/156]) compared with those in the placebo group (34% [n=53/156]).

Because maintenance of efficacy was demonstrated, the trial was ended early. Patients on INVEGA(R) SUSTENNA(TM) experienced a significant delay in time to relapse compared to placebo. Patients on placebo had a 3.6 fold higher incidence of experiencing relapse versus INVEGA(R) SUSTENNA(TM). As such, INVEGA(R) SUSTENNA(TM) has the potential to be of tremendous benefit for physicians, caregivers and patients.

In clinical trials, the most common adverse events (incidence greater than or equal to 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia and extrapyramidal disorder.

"INVEGA(R) SUSTENNA(TM) provides healthcare professionals the opportunity to rethink their overall approach to how they treat schizophrenia by using long-acting therapies," said Husseini Manji, M.D., F.R.C.P.C., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Pharmaceutical Research & Development. "The approval of INVEGA(R) SUSTENNA(TM) demonstrates our commitment to providing valuable novel therapies for schizophrenia. INVEGA(R) SUSTENNA(TM) has a demonstrated safety profile that can help healthcare professionals address the issue of medication adherence and can also help many patients delay the time to relapse."

Visit http://www.INVEGASUSTENNA.com for full prescribing information.

IMPORTANT SAFETY INFORMATION FOR INVEGA((R)) SUSTENNA(TM)

INVEGA((R)) SUSTENNA(TM) is not approved for the treatment of dementia-related psychosis in elderly patients. Elderly
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
2. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
3. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
4. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
5. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
6. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
7. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
8. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
9. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
10. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
11. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009).../ -- Reportlinker.com announces that a new market ..., Inflammatory Disorders: Therapies That Suppres...w.reportlinker.com/p0165600/Inflammatory-Disorders...ponse.html ,, The human immune system can go a...ing an exaggerated response to a foreign substance...
(Date:11/30/2009)... Jocelyn Rapelyea, Associate Director of Breast Im...sity Medical Center in Washington, D.C., demonstra...ific Gamma Imaging (BSGI) can be localized utilizi...l, as for pre-operative localization today at the ...h America (RSNA). ,, BSGI was conducted using a...
(Date:11/30/2009)...- Minimally-invasive procedures are increasingly r... oncology, cardiology and women,s health applicati...tion expected to reach $600 million by 2015, clini...mally-invasive procedures, including shorter patie...ter patient throughput. ,, (Logo: http://www...
Breaking Medicine Technology:Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 4Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 5Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 4Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 5Lexington Health Care Names New Chief Executive Officer 51899 1Lexington Health Care Names New Chief Executive Officer 51899 2Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 1Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 2Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 3Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 4PAL Health Technologies Wins State Level Prestigious Employer of the Year Award 51895 1PAL Health Technologies Wins State Level Prestigious Employer of the Year Award 51895 2
...ults of Roche and Ipsen,s First Once-Weekly Human ...iation Meeting -, NUTLEY, N.J., June 10 Roche an...poglutide (R1583) has been shown to provide,signif...oss after only,eight weeks of treatment(1,2) with ...try into Phase III. Taspoglutide, originating from...
...estigational Diabetes Therapy Also Improved Glucos... Taken Twice a Day, SAN FRANCISCO, June 9 Amylin...and Company (NYSE: LLY ), and Alkermes, Inc.,(Nas...k open-label clinical,study that showed the durabl... release formulation of exenatide. Patients taking...
Other Medicine Technology:Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 2Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 3Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 4Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 5Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9
(Date:11/30/2009)...s in animals , , MONDAY, Nov. 30 (Heal...that stem cells from transplanted human-derived um...heart disorders. , Scientists already know tha...st of different kinds of cells in the laboratory, ... Seoul, Korea, co-author of one of the studies, sa...
(Date:11/30/2009)...wire/ -- Kemin Foods, L.C. ("Kemin") and OmniActiv...Technologies, Ltd. ("OmniActive") have reached an ...agree that Kemin,s US Patent No. 5,382,714 ("the ,...cation and Recrystallization of Lutein from Saponi...reissues of that patent are valid and enforceable....
(Date:11/30/2009)...PRNewswire/ -- During this time of year, people be...oved one with Alzheimer,s disease or other form of...truggle with appropriate gift items. ,, Brookd...f senior living residences in the nation, includin...ggestions. ,, A listening device with recordin...
(Date:11/30/2009)... and Europa Uomo, the European,advocacy movement ...d into an,affiliated partnership as part of their...ient awareness in Europe with regards to urologica...ecretary-General of the EAU: "Thanks to this uniqu...in access to the latest information on,optimum su...
(Date:11/30/2009)...ched a series of clinical trials in order to asses... approach involves the application of personalised...rom the patient him or herself and designed to com...frequent malignant tumours. The new therapy is adm...the standard, first-line treatment involving surgi...
Breaking Medicine News(10 mins):Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6
...y hospital's inability to activate emergency power...ddle of a cataract surgery was awarded over Rs one... "It had taken about 15-20 minutes of crucial ...," observed the Consumer Disputes Redressal Forum ...
..., spread of infectious disease and food security u...ry in order to acquire the proper balance between ...phy professor of Kansas State University has used ...in uses remote sensing, in combination with other ...
...Toronto General Hospital, researchers have discove...ion //of specific repair cells from the bone marro...le it has long been known that bone marrow cells h... stem cells in repairing a damaged heart, restorin...
...a good 14 years has revealed that regular exercise...e body weight has an impact in cutting down the ri...uthor of the study, said "Even though erectile pro...." Obesity also affects sexual health, he said. ...
...f BARACLUDE? (entecavir) for the treatment of chro...proval by the Drug Controller General of India. ...atment of chronic hepatitis B virus infection in a... active disease. BARACLUDE? is an oral antiv...
...management training center, not only training Indi...tries//. The MV Hospital for Diabetes and Diabetes...zation’s collaborating centre for diabetes researc...e center is currently coaching a Pakistani physici...
Other Medicine News:Health News:Ecological Changes affects human health, food security 2Health News:Bone Marrow Cells Aid In Heart Repair 2Health News:Bone Marrow Cells Aid In Heart Repair 3Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
Cushing Burr
Doro J-Arm Retractor System
Molt 9
Langenbeck Periosteal Elevators
Medicine Products: